{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:37:17Z","timestamp":1767987437904,"version":"3.49.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>SARS-CoV-2 vaccines\u2019 effectiveness is not yet clearly known in immunocompromised patients. This study aims to assess the humoral and cellular specific immune response to SARS-CoV-2 vaccines and the predictors of poor response in patients with common variable immunodeficiency (CVID) phenotype and in patients treated with B-cell depletion therapies (BCDT), as well as the safety of these vaccines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From March to September 2021, we performed a prospective study of all adult patients who would receive the SARS-CoV-2 vaccination and were previously diagnosed with (i) a CVID syndrome (CVID phenotype group; n=28) or (ii) multiple sclerosis (MS) treated with B-cell depleting therapies three to six months before vaccination (BCD group; n=24). Participants with prior SARS-CoV-2 infection; or prior SARS-CoV-2 vaccine administration; or use of any immunosuppressant (except BCDT in MS group) were excluded. A group of subjects without any medical condition that confers immunosuppression and who met all study criteria was also assessed (control group; n=14). A chemiluminescence immunoassay was used to determine pre- and post-SARS-CoV-2 vaccine anti-S IgG antibodies. T-cell specific response was assessed by analysis of pre- and post-SARS-CoV-2 vaccination blood samples with an interferon-gamma release assay. The baseline blood sample also included several biochemical, haematological and immunological analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>SARS-CoV-2 vaccines are safe in immunocompromised patients, although their effectiveness was lower than in healthy individuals. CVID phenotype patients showed impaired humoral (29%) and cellular (29%) response, while BCD patients fundamentally presented humoral failure (54%). Low IgA values, low CD19+ peripheral B cells, low switched memory B cells, and a low CD4+\/CD8+ ratio were predictors of inadequate specific antibody response in CVID phenotype patients. No factor was found to predict poor cellular response in CVID phenotype patients, nor a defective humoral or cellular response in BCD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The effectiveness of SARS-CoV-2 vaccines in CVID phenotype and BCD patients is lower than in healthy individuals. Knowledge of predictive factors of humoral and cellular response failure in immunocompromised patients could be very useful in clinical practice, and thus, studies in this regard are clearly needed.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.895209","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T05:24:24Z","timestamp":1651209864000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Evaluation of Humoral and Cellular Immune Responses to the SARS-CoV-2 Vaccine in Patients With Common Variable Immunodeficiency Phenotype and Patient Receiving B-Cell Depletion Therapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Arnau","family":"Antol\u00ed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Rocamora-Blanch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Framil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virg\u00ednia","family":"Mas-Bosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Bermudez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Martinez-Yelamos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Dopico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Calatayud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Garcia-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Humberto","family":"Hern\u00e1ndez-Ben\u00edtez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Riera-Mestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Bas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Masuet-Aumatell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ra\u00fal","family":"Rigo-Bonnin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Morandeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Solanich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int J Antimicrob Agents."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105948","article-title":"Review of the 2019 Novel Coronavirus (SARS-CoV-2) Based on Current Evidence","volume":"55","author":"Wang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"B3","unstructured":"WHO Coronavirus (COVID-19) DashboardWHO Coronavirus (COVID-19) Dashboard With Vaccination Data"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.7326\/M21-1757","article-title":"Effect of Immunosuppression on the Immunogenicity of Mrna Vaccines to Sars-Cov-2 a Prospective Cohort Study","volume":"174","author":"Deepak","year":"2021","journal-title":"Ann Intern Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16713","article-title":"Effectiveness of SARS-CoV-2 Vaccination in Fully Vaccinated Solid Organ Transplant Recipients","volume":"21","author":"Malinis","year":"2021","journal-title":"Am J Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324789","article-title":"Infliximab Is Associated With Attenuated Immunogenicity to BNT162b2 and ChAdOx1 Ncov-19 SARS-CoV-2 Vaccines in Patients With IBD","volume":"70","author":"Kennedy","year":"2021","journal-title":"Gut"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220408","article-title":"SARS-CoV-2 Vaccination in Rituximab-Treated Patients: Evidence for Impaired Humoral But Inducible Cellular Immune Response","volume":"80","author":"Bonelli","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.12.1077","article-title":"Clinical Picture and Treatment of 2212 Patients With Common Variable Immunodeficiency","volume":"134","author":"Gathmann","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.06.044","article-title":"Primary Immunodeficiency Diseases: An Update","volume":"114","author":"Notarangelo","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377945","article-title":"The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity","volume":"7","author":"Seidel","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377945","article-title":"Morbidity and Mortality in Common Variable Immune Deficiency Over 4 Decades","volume":"119","author":"Resnick","year":"2012","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2010-01-254417","article-title":"How I Treat Common Variable Immune Deficiency","volume":"116","author":"Cunningham-Rundles","year":"2010","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.08.040.Secondary","article-title":"Secondary Immunodeficiencies, Including HIV Infection","volume":"125","author":"Javie Chinen","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/practneurol-2018-001899","article-title":"Rituximab in Neurological Disease: Principles, Evidence and Practice","volume":"19","author":"Whittam","year":"2019","journal-title":"Pract Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3949\/ccjm.87a.20056","article-title":"The Effect of Disease-Modifying Antirheumatic Drugs on Vaccine Immunogenicity in Adults","volume":"87","author":"Day","year":"2020","journal-title":"Cleve Clin J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.07.081","article-title":"Early Identification of COVID-19 Cytokine Storm and Treatment With Anakinra or Tocilizumab","volume":"99","author":"Langer-Gould","year":"2020","journal-title":"Int J Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00059-X","article-title":"COVID-19 Outcomes in Patients With Inflammatory Rheumatic and Musculoskeletal Diseases Treated With Rituximab: A Cohort Study","volume":"3","author":"Avouac","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.05.029","article-title":"Immunogenicity of Pfizer-BioNTech COVID-19 Vaccine in Patients With Inborn Errors of Immunity","volume":"148","author":"Hagin","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16618","article-title":"COVID-19 Infection in Solid Organ Transplant Recipients After SARS-CoV-2 Vaccination","volume":"21","author":"Wadei","year":"2021","journal-title":"Am J Transplant"},{"key":"B21","volume-title":"COVID-19 Vaccines: Authorised | European Medicines Agency","year":"2021"},{"key":"B22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40265-021-01480-7","article-title":"BNT162b2 mRNA COVID-19 Vaccine: First Approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2022483","article-title":"An mRNA Vaccine Against SARS-CoV-2 \u2014 Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and Immunogenicity of the ChAdOx1 Ncov-19 Vaccine Against SARS-CoV-2: A Preliminary Report of a Phase 1\/2, Single-Blind, Randomised Controlled Trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2034201","article-title":"Interim Results of a Phase 1\u20132a Trial of Ad26.COV2.S Covid-19 Vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines9080840","article-title":"Usefulness of Ivd Kits for the Assessment of Sars-Cov-2 Antibodies to Evaluate the Humoral Response to Vaccination","volume":"9","author":"Lukaszuk","year":"2021","journal-title":"Vaccines"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2016.05.006","article-title":"Multicenter Study for the Evaluation of the Antibody Response Against Salmonella Typhi Vi Vaccination (EMPATHY) for the Diagnosis of Anti-Polysaccharide Antibody Production Deficiency in Patients With Primary Immunodeficiency","volume":"169","author":"S\u00e1nchez-Ram\u00f3n","year":"2016","journal-title":"Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00059-1","article-title":"Anti-SARS-CoV-2 Antibodies in Healthy Donor Plasma Pools and IVIG Products","volume":"21","author":"Romero","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.627285","article-title":"Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications","volume":"12","author":"Dalakas","year":"2021","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S1473-3099(21)00755-6","article-title":"Anti-SARS-CoV-2 Antibodies in Healthy Donor Plasma Pools and IVIG Products \u2014 an Update","volume":"22","author":"Romero","year":"","journal-title":"Lancet Infect Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijid.2021.12.329","article-title":"Effective Presence of Antibodies Against Common Human Coronaviruses in Immunoglobulin Medicinal Products","volume":"116","author":"D\u00edez","year":"2022","journal-title":"Int J Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"103705","DOI":"10.1016\/j.ebiom.2021.103705","article-title":"Safety and Efficacy of the mRNA BNT162b2 Vaccine Against SARS-CoV-2 in Five Groups of Immunocompromised Patients and Healthy Controls in a Prospective Open-Label Clinical Trial","volume":"74","author":"Bergman","year":"2021","journal-title":"EBioMedicine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108730","article-title":"A Novel Application of Delayed-Type Hipersensitivity Reaction to Measure Cellular Immune Response in SARS-CoV-2 Exposed Individuals","volume":"226","author":"Barrios","year":"2021","journal-title":"Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11299","article-title":"Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis","volume":"3","author":"Ammitzb\u00f8ll","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01507-2","volume-title":"Cellular and Humoral Immune Responses Following SARS-CoV-2 MRNA Vaccination in Patients With Multiple Sclerosis on Anti-CD20 Therapy","author":"Apostolidis","year":"2021"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220781","article-title":"SARS-CoV-2 Vaccination in Rituximab-Treated Patients: B Cells Promote Humoral Immune Responses in the Presence of T-Cell-Mediated Immunity","volume":"80","author":"Mrak","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220626","article-title":"Humoral and T-Cell Responses to SARS-CoV-2 Vaccination in Patients Receiving Immunosuppression","volume":"80","author":"Prendecki","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1053\/j.gastro.2021.09.055","article-title":"Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis","volume":"162","author":"Sakuraba","year":"2022","journal-title":"Gastroenterology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102927","article-title":"Response to SARS-CoV-2 Vaccination in Immune Mediated Inflammatory Diseases: Systematic Review and Meta-Analysis","volume":"21","author":"Jena","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220503","article-title":"Disease Activity and Humoral Response in Patients With Inflammatory Rheumatic Diseases After Two Doses of the Pfizer mRNA Vaccine Against SARS-CoV-2","volume":"80","author":"Braun-Moscovici","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(21)00351-9","article-title":"Cellular and Humoral Immunity After the Third Dose of SARS-CoV-2 Vaccine in Patients Treated With Rituximab","volume":"4","author":"Felten","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/aci.0000000000000788","article-title":"An Immunologist\u2019s Perspective on Anti-COVID-19 Vaccines","volume":"21","author":"Milota","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(21)00333-7","article-title":"Humoral and Cellular Immunogenicity to a Second Dose of COVID-19 Vaccine BNT162b2 in People Receiving Methotrexate or Targeted Immunosuppression: A Longitudinal Cohort Study","volume":"4","author":"Mahil","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12339","article-title":"Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses","volume":"326","author":"Benotmane","year":"2021","journal-title":"JAMA - J Am Med Assoc"},{"key":"B46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.7326\/l21-0598","article-title":"Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series","volume":"63","author":"Caillard","year":"2022","journal-title":"Ann Intern Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0913-5","article-title":"A Serological Assay to Detect SARS-CoV-2 Seroconversion in Humans","volume":"26","author":"Amanat","year":"2020","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/SCIIMMUNOL.ABC8413","article-title":"The Receptor-Binding Domain of the Viral Spike Protein is an Immunodominant and Highly Specific Target of Antibodies in SARS-CoV-2 Patients","volume":"5","author":"Premkumar","year":"2020","journal-title":"Sci Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.895209\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T05:24:29Z","timestamp":1651209869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.895209\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2022.895209"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.895209","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]},"article-number":"895209"}}